Abbott (NYSE:ABT) announced today that it entered into a definitive agreement to acquire smart insulin management company Bigfoot Biomedical. The transaction remains subject to customary closing conditions and the companies declined to disclose financial terms. They expect it to close in the third quarter of 2023. Abbott has a longstanding relationship with Bigfoot going back […]
abbott
Abbott FreeStyle Libre 3 reader is now available, covered by Medicare
Abbott (NYSE:ABT) has made its FreeStyle Libre 3 reader available in the U.S., enabling people on Medicare to access the system. The FreeStyle Libre 3 reader pairs with the company’s latest continuous glucose monitor (CGM) sensor, cleared by the FDA last year. The addressable market for the sensor keeps growing, with massive coverage expansions all […]
Abbott Diabetes business booms in Q2, company set to submit new sensor in U.S. this year
Abbott (NYSE:ABT) today shared a number of positive updates on its Diabetes business as part of its second-quarter earnings report. The medtech giant’s Diabetes unit brought in sales of $1.4 billion in the quarter, marking 19.4% growth year-over-year. Its FreeStyle Libre continuous glucose monitors (CGMs) continue to drive growth as CEO Robert Ford projected earlier […]
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]
Abbott, ADA partner on therapeutic nutrition program for people with diabetes
Abbott (NYSE:ABT) and the American Diabetes Association (ADA) announced a collaboration to improve nutrition for people with diabetes. The duo aims to help better understand how diabetes technology, like continuous glucose monitoring (CGM), can help. They hope to aid people with diabetes make more informed decisions about their food and activity. Abbott develops a family […]
Insulet makes progress on integrating Omnipod 5 with Abbott FreeStyle Libre 2
Insulet (Nasdaq:PODD) today announced a duo of updates related to its Omnipod 5 system that includes a significant integration development. Acton, Massachusetts-based Insulet plans to discuss a range of developments related to its product line in the coming days at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego. Presentations include real-world evidence […]
France expands reimbursement for Abbott FreeStyle Libre 2 to all basal insulin users
Abbott (NYSE:ABT) announced today that the French health authority approved the expansion of reimbursement coverage for the FreeStyle Libre 2. FreeStyle Libre 2 previously only had coverage for people with type 1 and type 2 diabetes who require intensive insulin therapy. France’s expansion covers the continuous glucose monitor (CGM) for all people who use basal […]
Abbott FreeStyle Libre 3 authorized for automated insulin delivery in UK
Abbott (NYSE:ABT) announced that its FreeStyle Libre 3 continuous glucose monitor (CGM) received UK authorization for use in automated insulin delivery. Authorization enables FreeStyle Libre 3 — Abbott’s newest sensor — to work with the Ypsomed mylife YpsoPump and CamDiab’s CamAPS FX mobile app. The company called this a “major step forward” for type 1 […]
Dexcom, Abbott applaud Medicare expansion for CGMs
Dexcom (Nasdaq:DXCM) and Abbott (NYSE:ABT) both commended a change to Medicare policies that benefits continuous glucose monitor (CGM) users. Last month, the Centers for Medicare & Medicaid Services (CMS) published a final local coverage determination (LCD) expanding coverage for CGMs. The ruling has now gone into effect. CMS first published the LCD modifying coverage criteria for […]
Abbott breaks ground on FreeStyle Libre manufacturing plant in Ireland
Abbott (NYSE:ABT) today broke ground on a new FreeStyle Libre manufacturing facility in Kilkenny, Ireland. Jared Watkin, SVP for Abbott’s diabetes care business, shared the news of the groundbreaking in a LinkedIn post. In August 2022, Ireland announced Abbott’s plans to spend €440 million ($450 million) to expand its operations in Ireland. The investment included […]